Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 9 No 2 (2024): December

A Review of Hidradenitis Suppurativa (HS)
Tinjauan tentang Hidradenitis Suppurativa (HS)



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.10256
Published
September 29, 2024

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle, affecting intertriginous areas such as the axillae, perianal, and inguinal regions. It is more prevalent in females, with peak onset between ages 18 and 29. Specific Background: HS, characterized by nodules, abscesses, and sinus tract scarring, uses the Hurley staging system for disease severity classification, but its limitations exist due to its static clinical features. Knowledge Gap: Although several treatment modalities exist, ranging from antibiotics to surgery, there is no definitive therapy, and the pathogenesis remains poorly understood, complicating early diagnosis and management. Moreover, international diagnostic delays of 8-12 years further hinder patient outcomes. Aims: This study aims to explore the limitations of current classification and treatment approaches, while emphasizing the importance of prevention strategies and timely diagnosis to mitigate HS severity. Results: The Hurley classification, though widely used, fails to account for disease progression or quality of life. Current treatment options depend on disease severity, including topical and systemic antibiotics, hormonal therapies, biologics, and surgical interventions. Prevention strategies, such as laser hair removal and lifestyle modifications (e.g., smoking cessation, weight management), are essential to reducing disease impact. Novelty: This research highlights the under-explored role of early prevention and lifestyle interventions in managing HS and reducing progression through Hurley stages. Implications: Enhanced diagnostic tools, combined with early intervention strategies and a holistic approach to patient care, are necessary to improve clinical outcomes, reduce diagnostic delays, and minimize HS-related morbidity. Further research is needed to better understand the genetic and environmental factors contributing to HS pathogenesis.

Highlights:

 

  1. HS peaks in females aged 18-29 with chronic skin inflammation.
  2. 8-12 years diagnostic delay worsens disease severity and treatment.
  3. Prevention: laser hair removal, lifestyle changes reduce HS progression.

 

Keywords: Hidradenitis suppurativa, Hurley staging, inflammatory skin disease, prevention, diagnostic delays

References

  1. . C. Elisabete and B. Helena, "Managing Hidradenitis Suppurativa," 2019. DOI: 10.36959/446/38.
  2. . H. C. Ring et al., "The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls," JAMA Dermatology, vol. 153, no. 9, p. 897, Sep. 2017, doi: 10.1001/jamadermatol.2017.0904.
  3. . G. B. E. Jemec, "Hidradenitis Suppurativa," New England Journal of Medicine, vol. 366, no. 2, pp. 158–164, Jan. 2012, doi: 10.1056/nejmcp1014163.
  4. . K. Sellheyer and D. Krahl, "'Hidradenitis Suppurativa' is Acne Inversa! An Appeal to (Finally) Abandon a Misnomer," International Journal of Dermatology, vol. 44, no. 7, pp. 535–540, Dec. 2004, doi: 10.1111/j.1365-4632.2004.02536.x.
  5. . A. Mebazaa and R. Ben Hadid, "Hidradenitis Suppurativa: A Disease With Male Predominance in Tunisia," PubMed, Dec. 2009. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/20043054/.
  6. . A. Alikhan, P. J. Lynch, and D. B. Eisen, "Hidradenitis Suppurativa: A Comprehensive Review," Journal of the American Academy of Dermatology, vol. 60, no. 4, pp. 539–561, Apr. 2009, doi: 10.1016/j.jaad.2008.11.911.
  7. . Ł. Matusiak, A. Bieniek, and J. C. Szepietowski, "Hidradenitis Suppurativa Markedly Decreases Quality of Life and Professional Activity," Journal of the American Academy of Dermatology, vol. 62, no. 4, pp. 706-708.e1, Apr. 2010, doi: 10.1016/j.jaad.2009.09.021.
  8. . M. Napolitano et al., "Hidradenitis Suppurativa: From Pathogenesis to Diagnosis and Treatment," Clinical Cosmetic and Investigational Dermatology, vol. 10, pp. 105–115, Apr. 2017, doi: 10.2147/ccid.s111019.
  9. . L. R. Paus et al., "What Causes Hidradenitis Suppurativa?," Experimental Dermatology, vol. 17, no. 5, pp. 455–456, May 2008, doi: 10.1111/j.1600-0625.2008.00712_1.x.
  10. . E. Prens and I. Deckers, "Pathophysiology of Hidradenitis Suppurativa: An Update," Journal of the American Academy of Dermatology, vol. 73, no. 5, pp. S8–S11, Nov. 2015, doi: 10.1016/j.jaad.2015.07.045.
  11. . F. Canoui-Poitrine et al., "Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study," Journal of Investigative Dermatology, vol. 133, no. 6, pp. 1506–1511, Jun. 2013, doi: 10.1038/jid.2012.472.
  12. . A. Garg, J. Lavian, G. Lin, A. Strunk, and A. Alloo, "Incidence of Hidradenitis Suppurativa in the United States: A Sex- and Age-Adjusted Population Analysis," Journal of the American Academy of Dermatology, vol. 77, no. 1, pp. 118–122, Jul. 2017, doi: 10.1016/j.jaad.2017.02.005.
  13. . K. Kridin, E. Shavit, G. Damiani, and A. D. Cohen, "Hidradenitis Suppurativa and Rheumatoid Arthritis: Evaluating the Bidirectional Association," Immunologic Research, vol. 69, no. 6, pp. 533–540, Aug. 2021, doi: 10.1007/s12026-021-09221-4.
  14. . A. Rondags, S. Arends, F. R. Wink, B. Horváth, and A. Spoorenberg, "High Prevalence of Hidradenitis Suppurativa Symptoms in Axial Spondyloarthritis Patients: A Possible New Extra-Articular Manifestation," Seminars in Arthritis and Rheumatism, vol. 48, no. 4, pp. 611–617, Feb. 2019, doi: 10.1016/j.semarthrit.2018.03.010.
  15. . Y. Yao and S. F. Thomsen, "The Role of Interleukin-17 in the Pathogenesis of Hidradenitis Suppurativa," PubMed, Jul. 2017. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/29469692/.
  16. . H. H. Van Der Zee and G. B. E. Jemec, "New Insights Into the Diagnosis of Hidradenitis Suppurativa: Clinical Presentations and Phenotypes," Journal of the American Academy of Dermatology, vol. 73, no. 5, pp. S23–S26, Nov. 2015, doi: 10.1016/j.jaad.2015.07.047.
  17. . C. C. Zouboulis, Q. Ju, and L.-H. F. Xiang, "Editorial — The 3rd International Conference on Sebaceous Gland, Acne, Rosacea and Related Disorders," Dermato-Endocrinology, vol. 9, no. 1, p. e1386419, Jan. 2017, doi: 10.1080/19381980.2017.1386419.
  18. . H. Kurzen and M. Kurzen, "Secondary Prevention of Hidradenitis Suppurativa," Dermatology Reports, vol. 11, no. 2, Oct. 2019, doi: 10.4081/dr.2019.8243.
  19. . R. Sabat et al., "Acne Inversa/Hidradenitis Suppurativa: Ein Update," Der Hautarzt, vol. 68, no. 12, pp. 999–1006, Nov. 2017, doi: 10.1007/s00105-017-4082-5.
  20. . J. Boer, M. Nazary, and P. T. Riis, "The Role of Mechanical Stress in Hidradenitis Suppurativa," Dermatologic Clinics, vol. 34, no. 1, pp. 37–43, Jan. 2016, doi: 10.1016/j.det.2015.08.011.
  21. . G. Kelly, C. M. Sweeney, A. Tobin, and B. Kirby, "Hidradenitis Suppurativa: The Role of Immune Dysregulation," International Journal of Dermatology, vol. 53, no. 10, pp. 1186–1196, Jun. 2014, doi: 10.1111/ijd.12550.
  22. . E. Prens and I. Deckers, "Pathophysiology of Hidradenitis Suppurativa: An Update," Journal of the American Academy of Dermatology, vol. 73, no. 5, pp. S8–S11, Nov. 2015, doi: 10.1016/j.jaad.2015.07.045.
  23. . G. Kelly et al., "Dysregulated Cytokine Expression in Lesional and Nonlesional Skin in Hidradenitis Suppurativa," British Journal of Dermatology, vol. 173, no. 6, pp. 1431–1439, Nov. 2015, doi: 10.1111/bjd.14075.
  24. . J. Molnar et al., "Hidradenitis Suppurativa and 1-Carbon Metabolism: Role of Gut Microbiome, Matrix Metalloproteinases, and Hyperhomocysteinemia," Frontiers in Immunology, vol. 11, Aug. 2020, doi: 10.3389/fimmu.2020.01730.
  25. . J. Boer and G. B. E. Jemec, "Mechanical Forces and Hidradenitis Suppurativa," Experimental Dermatology, vol. 30, no. 2, pp. 212–215, Nov. 2020, doi: 10.1111/exd.14234.
  26. . Here’s your reference list formatted in IEEE style, with titles and journal names in Title Case, and non-Latin letters converted to Latin letters. I’ve also completed any missing details based on available information.
  27. . F. M. S. Al-Ali, D. M. Al-Jabri, M. D. Al-Balushi, and H. A. Al-Mamari, “Hidradenitis Suppurativa (Or Acne Inversa) With Autosomal Dominant Inheritance Is Not Linked to Chromosome 1p21.1-1q25.3 Region,” Exp. Dermatol., vol. 19, no. 9, pp. 851–853, Aug. 2010, doi: 10.1111/j.1600-0625.2010.01088.x.
  28. . H. H. Zee, K. Winter, C. J. Woude, and E. P. Prens, “The Prevalence of Hidradenitis Suppurativa in 1093 Patients With Inflammatory Bowel Disease,” Br. J. Dermatol., vol. 171, no. 3, pp. 673–675, Jul. 2014, doi: 10.1111/bjd.13002.
  29. . C. C. Zouboulis et al., “European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa,” J. Eur. Acad. Dermatol. Venereol., vol. 29, no. 4, pp. 619–644, Jan. 2015, doi: 10.1111/jdv.12966.
  30. . R. Alhusayen and N. H. Shear, “Pharmacologic Interventions for Hidradenitis Suppurativa,” Am. J. Clin. Dermatol., vol. 13, no. 5, pp. 283–291, Oct. 2012, doi: 10.2165/11631880-000000000-00000.
  31. . T. Shih, K. Lee, J. R. Seivright, D. R. De, V. Y. Shi, and J. L. Hsiao, “Hyperhidrosis Treatments in Hidradenitis Suppurativa: A Systematic Review,” Dermatol. Ther., vol. 35, no. 1, pp. 1–10, Nov. 2021, doi: 10.1111/dth.15210.
  32. . S. S. Jafari, E. Knüsel, S. Cazzaniga, and R. Hunger, “A Retrospective Cohort Study on Patients With Hidradenitis Suppurativa,” J. Am. Acad. Dermatol., vol. 78, no. 1, pp. 25–29, Jan. 2018.
  33. . S. M. S. Jafari, R. E. Hunger, and C. Schlapbach, “Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm,” Front. Med., vol. 7, p. 68, Mar. 2020, doi: 10.3389/fmed.2020.00068.
  34. . M. Gierek, D. Kitala, W. Łabuś, K. Szyluk, P. Niemiec, and G. Ochała-Gierek, “Impact of Hidradenitis Suppurativa Surgical Treatment on Health-Related Life Quality,” J. Clin. Med., vol. 11, no. 15, p. 4327, Jul. 2022, doi: 10.3390/jcm11154327.
  35. . A. S. L. E. de Oliveira, G. Bloise, G. Moltrasio, C. Coelho, A. Agrelli, A. Moura, R. Tricarico, P. M. Jamain, S. Marzano, A. V. Crovella, and S. et al., “Transcriptome Meta-Analysis Confirms the Hidradenitis Suppurativa Pathogenic Triad: Upregulated Inflammation, Altered Epithelial Organization, and Dysregulated Metabolic Signaling,” Biomolecules, vol. 12, no. 1371, 2022, doi: 10.3390/biom12101371.
  36. . N. Tanaka, A. Fujioka, S. Tajima, A. Ishibashi, S. Hirose, “Elafin Is Induced in Epidermis in Skin Disorders With Dermal Neutrophilic Infiltration: Interleukin-1 Beta and Tumour Necrosis Factor-Alpha Stimulate Its Secretion In Vitro,” Br. J. Dermatol., vol. 143, pp. 728–732, 2000, doi: 10.1046/j.1365-2133.2000.03802.x.
  37. . A. Morita, H. Takahashi, K. Ozawa, S. Imafuku, N. Takekuni, K. Takahashi, T. Matsuyama, Y. Okubo, Y. Zhao, S. Kitamura, and et al., “Long-Term Analysis of Adalimumab in Japanese Patients With Moderate to Severe Hidradenitis Suppurativa: Open-Label Phase 3 Results,” J. Dermatol., vol. 48, no. 1, pp. 3–13, 2021, doi: 10.1111/1346-8138.15530.
  38. . C. Marasca, M. C. Annunziata, A. Villani, S. Volpe, D. Marasca, and G. Fabbrocini, “Adalimumab Versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study,” J. Drugs Dermatol., vol. 18, no. 4, pp. 437–438, 2019.
  39. . O. Join-Lambert, F. Ribadeau-Dumas, V. Jullien, M.-D. Kitzis, J.-P. Jais, H. Coignard-Biehler, H. Guet-Revillet, P.-H. Consigny, M. Delage, M. Nassif, and et al., “Dramatic Reduction of Clindamycin Plasma Concentration in Hidradenitis Suppurativa Patients Treated With the Rifampin-Clindamycin Combination,” Eur. J. Dermatol., vol. 24, no. 1, pp. 94–95, Jan. 2014.
  40. . D. M. L. Saunte and G. B. E. Jemec, “Hidradenitis Suppurativa: Advances in Diagnosis and Treatment,” JAMA, vol. 318, no. 20, pp. 2019–2032, Nov. 2017, doi: 10.1001/jama.2017.18282.
  41. . H. Guet-Revillet, J. P. Jais, M. N. Ungeheuer, H. Coignard-Biehler, S. Duchatelet, M. Delage, and et al., “The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study,” Clin. Infect. Dis., vol. 65, no. 2, pp. 282–291, Jul. 2017, doi: 10.1093/cid/cix296.
  42. . S. Pradhan, B. Madke, P. Kabra, and A. L. Singh, “Anti-Inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology,” Indian J. Dermatol., vol. 61, no. 5, pp. 469–481, Oct. 2016, doi: 10.4103/0019-5154.190972.
  43. . C. Marasca, P. Tranchini, V. Marino, M. C. Annunziata, M. Napolitano, D. Fattore, and et al., “The Pharmacology of Antibiotic Therapy in Hidradenitis Suppurativa,” Expert Rev. Clin. Pharmacol., vol. 13, no. 5, pp. 521–530, May 2020, doi: 10.1080/17512433.2020.1766785.
  44. . M. J. Diaz, S. Aflatooni, P. Abdi, R. Li, M. R. Anthony, S. Neelam, C. Farkouh, J. T. Tran, S. Svoboda, M. Forouzandeh, and et al., “Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management—A Systematic Review,” Curr. Issues Mol. Biol., vol. 45, pp. 4400–4415, 2023, doi: 10.3390/cimb45050280.

Downloads

Download data is not yet available.